newsfilter
← Latest News
GlobeNewswire·

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

IMCR
  • Immunocore presented Phase 1/2 data at the 2026 SITC Annual Meeting regarding brenetafusp alone & in combination with KIMMTRAK for HLA-A*02:01-positive metastatic uveal melanoma.
  • In 17 first-line patients treated with the combination, the two-year overall survival rate was 70% with a median follow-up of 29 months where median overall survival was not reached.
  • The combination achieved a 29% overall response rate, a 71% disease control rate, & a median duration of response of 24 months.
  • 64% of patients with an overall survival exceeding 2 years received only the brenetafusp & KIMMTRAK combination.
  • Molecular response data showed 89% of evaluable patients had a molecular response, with 44% achieving ctDNA clearance.
  • The safety profile was generally well tolerated with no new safety signals, though cytokine release syndrome occurred in 77% of combination patients (mostly Grade 1 or 2).
  • No treatment-related adverse events led to discontinuation or death in either the combination or monotherapy groups.
  • The company plans to initiate the DUET-UVEAL randomized Phase 2/3 trial to further evaluate the combination in unresectable or metastatic uveal melanoma.
  • Brenetafusp is an investigational ImmTAC molecule targeting PRAME, while KIMMTRAK targets gp100, aiming to enhance T cell-mediated tumor killing through dual engagement.
  • For brenetafusp monotherapy in second-line or later settings (16 evaluable patients), the overall response rate was 19%, disease control rate was 63%, & two-year overall survival was 31%.
Company
Immunocore Holdings plc
Keywords
Nasdaq:IMCR, Immunocore Holdings plc, brenetafusp, tebentafusp, uveal melanoma, Immunocore